Back to top

Image: Bigstock

Edwards Lifesciences Corp.

Read MoreHide Full Article

Edwards Lifesciences exited the first quarter of 2017 on a solid note, with both earnings and revenues beating the Zacks Consensus Estimate. Strong THVT sales were a major upside for the company. The company also performed well on the gross margin front. This bullish result has been reflected in the company’s share price performance too. Over the last three months, Edwards was trading below the broader Medical instruments industry. However, the stock shot up post the first-quarter earnings release. Management expects to gain space in the potential THV market, based on increasing preference in favor of TAVR as well as compelling clinical evidences. On the flip side, higher operating expenses continue to be a concern. The stock’s valuation also remains stretched on huge investments in the launch and promotion of products. Stiff competition, currency fluctuation and reimbursement issues are other challenges for the company.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Edwards Lifesciences Corporation (EW) - free report >>

Published in